About this episode

This episode discusses a significant RCT on the Blys/APRIL inhibitor telitacicept for SLE patients and its potential FDA implications.

Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one. Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719

More episodes of The Evidence Based Rheumatology Podcast

• E134: Brepocitinib in Dermatomyositis (VALOR) · April 17, 2026 · 15 min
• E133: Obinutuzumab for SLE (ALLEGORY) · March 19, 2026 · 15 min
• E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE) · March 5, 2026 · 14 min
• E131: A Sham-Controlled Sham of a Trial: RESET-RA · January 21, 2026 · 15 min
• E129: Long Term Routine Laboratory Monitoring in RA · December 4, 2025 · 15 min
• E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD) · November 12, 2025 · 19 min

Explore listener stats, chart rankings, contacts and more on the The Evidence Based Rheumatology Podcast podcast page.